Precigen, Inc.

NASDAQ:PGEN

Biotechnology

Healthcare
$4.16 -2.08%

-$0.10 today

Market cap
$1.49B
Beta
1.06
P/E (TTM)
-7.1
EPS (TTM)
-$0.65
52W Low $1.39High $5.47

Volume 4.37M

Average 4.72M

Returns on capital

Precigen, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-1198.6%

avg -215.5%

ROIC

-88.5%

avg -47.1%

ROA

-160.0%

avg -48.0%

Analysis

ROIC is currently the strongest return metric at -88.5% versus its period average of -47.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Helen Sabzevari

President, Chief Executive Officer & DirectorUSD 2.07M64229.17K0.08%

Donald Lehr

Chief Legal Officer & Corporate SecretaryUSD 754.15K51——

Phil Tennant

Chief Commercial OfficerUSD 691.55K56120.83K0.04%

Rutul R. Shah

Chief Operating OfficerUSD 676.1K4573.30K0.02%

Harry Thomasian Jr.

Chief Financial OfficerUSD 655.52K6446.81K0.02%

Randal J. Kirk

Executive ChairmanUSD 100K73302.21K0.10%

Amy R. Lankford

Senior VP & Global Head of Regulatory Affairs————

Bryan T. Butman

Senior Vice President & Head of CMC—73——

Douglas E. Brough

Senior Vice President & Head of Research—71——

Steven Harasym

Vice President & Head of Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 23, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$24,661.53

Sells

41

$39.93M

Net Transaction Value

−$39.91M

Net selling

Most Active

KIRK RANDAL J

24 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 26, 26

KINDLER JEFFREY B

Direct

Sell$1.4M
Aug 25, 26

Shah Rutul R

Direct

Sell$115.1K
Aug 25, 26

Tennant Phil

Direct

Sell$593.7K
Aug 21, 26

AGEE NANCY H

Direct

Buy$24.7K
Aug 21, 26

Shah Rutul R

Direct

Sell$259.9K
Aug 6, 26

Shah Rutul R

Direct

Sell$224.6K
Aug 3, 26

Shah Rutul R

Direct

Sell$219.5K
Jul 31, 26

Thomasian Harry Jr.

Direct

Sell$606K
Jul 1, 26

Thomasian Harry Jr.

Direct

Sell$948K
Jun 29, 26

Shah Rutul R

Direct

Sell$251.1K

1–10 of 42

Summary

Insiders reported 1 buys worth $24,661.53 and 41 sells worth $39.93M over the last 12 months. That adds up to net selling of $39.91M. KIRK RANDAL J was the most active insider with 24 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-28.9%
+152.8% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -28.9% over three years. Forward estimates point to Revenue at +152.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Precigen, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PGEN's management, answered from reported figures.

Who manages PGEN?

Precigen, Inc. (PGEN) lists 10 active executives. The top listed executive is Amy R. Lankford, Senior VP & Global Head of Regulatory Affairs.

Are PGEN insiders buying or selling?

Recent insider activity shows net selling of $34.84M.